Stock price Loading… More on Euronext » General Stock Market Euronext Paris – Eurolist (compartiment C) Reuters / Bloomberg TRNG.PA / TNG.FP ISIN Code FR0005175080 Total number of shares outstanding 132,293,932 Initial Public Offering (IPO) March 26, 1998 Local Sector Index Next Biotech Financial Year Ends December 31
Author: alcyon
Information boursière
Financial information
Financial reports
Years Quarter Interim Registration Document First Second Third Fourth 2024 XBRL(fr) 2023 XBRL(fr) Amendment(fr) 2022 XBRL(fr) 2021 XBRL(fr) 2020 2019 … Continue reading Financial reports
Key figures
In € million except share and per share data 2023 2022 2021 2020 2019 Revenue 7.9 10.3 17.4 9.9 13.7 R&D Expense -29.6 -32.2 -32.9 -27.3 -31.4 G&A Expense -7.0 -7.9 -7.4 -6.5 -7.1 Net income (loss) -22.3 -32.8 -19.5 -17.2 -18.8 Net Cash Burn -24.0 -22.8 -10.0 -17.0 -20.5 Cash & Cash Equivalents 15.7… Continue reading Key figures
produits : 5 OVs teaser
AstraZeneca Transgene and AstraZeneca have entered into a collaboration agreement under which Transgene designs five innovative oncolytic viruses based on the Invir.IO™ platform. AstraZeneca can exercise an option on each of these candidates.
produits : TG6050
TG6050 Induce an immune response against tumors resistant to available treatments TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously. By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected… Continue reading produits : TG6050
produits : BT-001 teaser
BT-001 BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse. This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was… Continue reading produits : BT-001 teaser
Transgene Participates in New Cancer Research Consortium
Transgene Participates in New Cancer Research Consortium